Kadimastem - Stem Cell to Cure Diseases

Drug Discovery > Neural Diseases

Optimizing Drug Development through the use of pluripotent stem cell-derived human cells

Kadimastem’s unique capabilities enable high throughput screening of lead drug candidates. Our system is capable of screening compounds automatically and quantitatively using a cell-based microscope High Content Screening (HCS) system.

Kadimastem screening platform Highlights:

  • Unique accesses to human cell source
  • Replicable data
  • High content visual screening
  • Highly accurate
  • Shorten hit to lead phase 

Kadimastem drug screening system for research use currently includes the followings:

  • Oligodendrocyte Progenitor Cell (OPC) commitment assay - Human neural stem cells (NSC) that commit into oligodendrocyte precursor cells.
  • Oligodendrocyte differentiation assay - Human OPC differentiation toward mature oligodendrocytes.
  • Myelination assay - Human oligodendrocytes that myelinate neuron axons.

Human oligodendrocytes drug screening assays:

This platform ables access to an exclusive and highly sensitive drug screening system for therapeutic agents against Human demyelinating diseases such as Multiple Sclerosis (MS) and spinal cord traumas. In these demyelinating diseases the therapeutic challenge is how to stimulate sufficient differentiation and remyelination of OPC in order to restore neural functionality, and prevent further deterioration. The current use of rodent OPC for identifying active compounds that stimulates OPC has been shown as unreliable in predicting compound efficacy in humans (Merrill J.E 2009, Neuropsychopharmacology).

Kadimastem Oligodendrocyte drug screening assays enables the company:

  • Homogeneous and consistent population of OPCs as a reliable starting material for HCS assays generated from Kadimastem patented protocols.
  • Primary screen (Hit screen) to identify potential candidates that promote OPC differentiation and myelination.
  • Secondary screen (Lead compound screen) with generation of EC50/IC50 data for further pharmacological testing.
  • Proprietary algorithms to help evaluate OPC cultures and their interaction with compounds of interest.